G3BP1

Ras GTPase-activating protein-binding protein 1

Score: 0.660 Price: $0.66 Medium Druggability Status: active Wiki: G3BP1

🧠 Neurodegeneration

HYPOTHESES

PAPERS

KG EDGES

559

DEBATES

3D Protein Structure

🧬 G3BP1 — PDB 4FCJ Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

Medium

Score: 0.47

Clinical Stage

Phase II

Target Class

Signaling Protein

Safety

0.50

Druggability Analysis

Drug Development0.30

Structural Tractability0.85

Target Class0.50

Safety Profile0.50

Key Metrics

PDB Structures:

Known Drugs:

Approved:

In Clinical Trials:

Drug Pipeline (1 compounds)

1 Preclinical

Therapeutic Areas:

Amyotrophic Lateral Sclerosis (ALS) Frontotemporal Dementia (FTD) Neurodegeneration Protein aggregation disorders RNA metabolism dysfunction Neurodegenerative diseases with TDP-43/FUS pathology

Druggability Rationale: G3BP1 presents medium druggability (0.55) due to available structural data (18 PDB structures, 1.62 Å resolution) and defined protein domains, but is challenged by its primary role as an RNA-binding protein and stress granule scaffolding component, which favors protein-protein interactions over traditional small-molecule binding. The investigational status of resveratrol demonstrates early-stage tractability, though off-target effects highlight the difficulty in achieving selective G3BP1 inhibition via conventional approaches.

Mechanism: G3BP1 inhibitors would prevent stress granule assembly and stabilization by disrupting the interaction between G3BP1 and its binding partners, potentially reducing pathological aggregation of TDP-43 and FUS proteins. This mechanism could alleviate neurodegeneration in conditions characterized by aberrant stress granule formation and RNA metabolism dysfunction.

Drug Pipeline (1 compounds)

1 Preclinical

Known Drugs:

Resveratrol (investigational) — Stress granule modulator, neuroprotection (off-target)

Structural Data:

PDB (18) ✓AlphaFold ✓Cryo-EM ✓

3Q90 4FCJ 4FCM 4IIA 6TA7+13 more

UniProt: A0A7I2V3C4

Binding Pocket Analysis:

G3BP1 features a structured NTF2-like domain and RNA-recognition motif (RRM) identified across high-resolution crystal structures; binding pockets are likely present at protein-protein interaction interfaces and potentially at RNA-binding surfaces rather than a classical ATP-binding cavity. Cryo-EM and AlphaFold data suggest allosteric regulatory sites on the stress granule assembly interface may offer more selective targeting opportunities than direct active-site inhibition.

🧬 3D Protein Structure

🧬 G3BP1 — PDB 4FCJ Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

G3BP1 selectivity is complicated by its structural homology to G3BP2 and other RNA-binding proteins, as well as its multiple functional domains (NTF2-like domain, RRM, acidic regions) that may interact with numerous cellular partners. Off-target engagement with stress response pathways and RNA metabolism machinery presents a significant risk, requiring careful structural optimization to achieve isoform selectivity without disrupting essential cellular stress responses.